Results 11 to 20 of about 1,707,497 (360)

Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series

open access: yesBMC Cardiovascular Disorders, 2020
Background Pericardial constriction is one of the complications of purulent pericarditis (PP). Most difficult to treat, which may develop both in early and in the late period of the disease, resulting in a very poor prognosis.
Małgorzata Dybowska   +4 more
doaj   +1 more source

Factors Predictive for Immunomodulatory Therapy Response and Survival in Patients with Hypersensitivity Pneumonitis—Retrospective Cohort Analysis

open access: yesDiagnostics, 2022
Hypersensitivity pneumonitis (HP) is one of the interstitial lung diseases with clearly established diagnostic criteria. Nevertheless, pharmacologic treatment recommendations are still lacking. Most specialists use steroids as first-line drugs, sometimes
Katarzyna B. Lewandowska   +11 more
doaj   +1 more source

Pulmonary amyloidosis mimicking interstitial lung disease and malignancy - A case series with a review of a pulmonary patterns

open access: yesRespiratory Medicine Case Reports, 2021
Background: Amyloidosis is an uncommon condition, which results from accumulation of misfolded extracellular insoluble protein in tissues and organs of the body, causing its damage and dysfunction.
Katarzyna Zimna   +4 more
doaj   +1 more source

Tuberculous Pericarditis—Own Experiences and Recent Recommendations

open access: yesDiagnostics, 2022
Tuberculous pericarditis (TBP) accounts for 1% of all forms of tuberculosis and for 1–2% of extrapulmonary tuberculosis. In endemic regions, TBP accounts for 50–90% of effusive pericarditis; in non-endemic, it only accounts for 4%.
Małgorzata Dybowska   +6 more
doaj   +1 more source

Interstitial lung disease [PDF]

open access: yesEuropean Respiratory Review, 2014
Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with substantial morbidity and mortality. Knowledge achieved in recent years has resulted in the publication of the new classification of idiopathic interstitial pneumonias, according to which there are three groups: major, rare and unclassified.
Antoniou, Katerina M.   +5 more
openaire   +4 more sources

Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension—A Challenging Mystery

open access: yesDiagnostics, 2023
Sarcoidosis has been a well-recognised risk factor for pulmonary hypertension (PH) for a long time, but still, the knowledge about this concatenation is incomplete.
Aneta Kacprzak   +2 more
doaj   +1 more source

Pulmonary Hypertension in the Course of Interstitial Lung Diseases—A Personalised Approach Is Needed to Identify a Dominant Cause and Provide an Effective Therapy

open access: yesDiagnostics, 2023
The prevalence of pulmonary hypertension (PH) complicating interstitial lung diseases (ILDs) is 3.5–15% at an early stage, and up to 90% in ILD patients listed for lung transplantation.
Aneta Kacprzak   +2 more
doaj   +1 more source

Serum Levels of Interleukin-8 and Tumor Necrosis Factor-alpha in Coal Workers' Pneumoconiosis: One-year Follow-up Study

open access: yesSafety and Health at Work, 2010
Objectives: Various cytokines induced by inhalation of coal dust may mediate inflammation and lead to tissue damage or fibrosis, such as coal workers' pneumoconiosis (CWP).
Jong Seong Lee   +5 more
doaj   +1 more source

Imaging Plays a Key Role in the Diagnosis and Control of the Treatment of Bone Sarcoidosis

open access: yesBiomedicines, 2023
Sarcoidosis is a multisystem granulomatous disease of unknown origin. The most frequent localizations are thoracic lymph nodes and/or parenchymal lung disease, nevertheless any other organ may be involved.
Katarzyna Błasińska   +4 more
doaj   +1 more source

Guanylyl cyclase activation reverses resistive breathing–induced lung injury and inflammation [PDF]

open access: yes, 2015
Inspiratory resistive breathing (RB), encountered in obstructive lung diseases, induces lung injury. The soluble guanylyl cyclase (sGC)/cyclic guanosine monophosphate (cGMP) pathway is down-regulated in chronic and acute animal models of RB, such as ...
Brouckaert, Peter   +15 more
core   +2 more sources

Home - About - Disclaimer - Privacy